title: Update on the management of high-risk squamous cell carcinoma.
abstract: Cutaneous squamous cell carcinoma (CSCC) is the second most common malignancy occurring in white patients in the United States and incidence rates are increasing. While the majority of the 87,000-760,000 cases that occur yearly in the U.S. are curable, 4% develop lymph node metastases and 1.5% die from the disease. Given the frequency of occurrence of CSCC, it is estimated to cause as many deaths yearly as melanoma, with the majority occurring in patients with high risk tumors or in those at high risk for metastasis due to a variety of host factors, most commonly systemic immunosuppression. There are currently no standardized prognostic or treatment models to assist clinicians in most effectively identifying and managing these patients. Identification of patients at risk for poor outcomes as well as standardization regarding classification, staging, and treatment of high-risk tumors is critical for optimizing patient care. In this article, available literature on the classification and management of high risk CSCC is briefly summarized, emphasizing new information.
authors.affiliation: Department of Dermatology, Dana Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02130, USA.
authors.forename: Nicole R
authors.initials: NR
authors.lastname: LeBoeuf
authors.forename: Chrysalyne D
authors.initials: CD
authors.lastname: Schmults
mesh_terms: D002294:Carcinoma, Squamous Cell / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D016867:Immunocompromised Host; D018714:Radiotherapy, Adjuvant; D012878:Skin Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy*